Ashraf Badros

University of Maryland, Baltimore — United States

Medicine · Health Sciences

63h-index15.3kcitations325works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(239), Protein Degradation and Inhibitors(100), Chronic Lymphocytic Leukemia Research(44), Immunotherapy and Immune Responses(37), CAR-T cell therapy research(37)

Publications325 total

Atypical neurotoxicity in CAR-T cell therapy: A retrospective analysis of unusual icans presentations and their clinical implications
Blood·2025
Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study
Blood·2025
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Blood·2025· 1 citedOpen Access
Impact and predictors of icans on survival in lymphoma and myeloma patients treated with CAR T cell therapy
Blood·2025
Take the reins: a study protocol of a randomized controlled trial testing the effects of time-restricted eating vs. nutrition control on cancer-related fatigue among survivors of hematological malignancies
BMC Nutrition·2025Open Access
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
Blood Cancer Journal·2025Open Access
Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study
Clinical Lymphoma Myeloma & Leukemia·2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
Nature Communications·2025· 5 citedOpen Access
Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study
Haematologica·2025Open Access
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2025
Abstract 869: Distinct expansion, phenotype, function, and toxicity of cilta-cel vs. ide-cel CAR T cells in the real world
Cancer Research·2025
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
UNC Libraries·2025Open Access
Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: a randomized controlled trial
Supportive Care in Cancer·2025· 1 cited
Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: A randomized controlled trial
2024Open Access
Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
Blood·2024· 2 cited
Effects of Denosumab Therapy on Renal Function in Multiple Myeloma Patients: A Single Center Retrospective Analysis
Blood·2024· 1 citedOpen Access
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Blood·2024· 38 citedOpen Access
OA-45 Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study
Clinical Lymphoma Myeloma & Leukemia·2024
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients
Clinical Lymphoma Myeloma & Leukemia·2024
MM-359 Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients
Clinical Lymphoma Myeloma & Leukemia·2024
page 1 of 17Next →

Frequent Co-authors

Bart Barlogie(15), Guido Tricot(13), Maurizio Zangari(12), Aaron P. Rapoport(10), Raman Desikan(10), Elias Anaissie(9), Athanasios Fassas(9), Philippe Moreau(8), Paul G. Richardson(8), Christopher Morris(8), Olga Goloubeva(7), Saad Z. Usmani(7), Xavier Leleu(7), Sundar Jagannath(7), Meletios Α. Dimopoulos(7), Nikhil C. Munshi(7), David S. Siegel(6), Joan Bladé(6), Brian G.M. Durie(6), Amir A. Toor(6)